Predictors of haemodynamic instability during the changeover of norepinephrine infusion pumps by unknown
Cour et al. Ann. Intensive Care  (2016) 6:38 
DOI 10.1186/s13613-016-0139-3
RESEARCH
Predictors of haemodynamic instability 
during the changeover of norepinephrine 
infusion pumps
Martin Cour1,2, Thomas Bénet3,4, Romain Hernu1, Marie Simon1, Thomas Baudry1, Philippe Vanhems3,4 
and Laurent Argaud1,2*
Abstract 
Background: Changeovers of norepinephrine infusion pumps (CNIPs) frequently lead to haemodynamic instability. 
The aim of this study was to identify risk factors for haemodynamic instability associated with CNIP, independent of 
the method used to perform the relay.
Methods: We performed a prospective study, in a university-affiliated intensive care unit. Over a 1-year period, all 
adult patients who had at least one CNIP were included. CNIPs were automatically performed using smart pumps, in 
accordance with a standardised protocol. CNIP-induced haemodynamic instability was defined as a variation in mean 
arterial pressure (MAP) >25 %. A multivariate mixed effects logistic regression was fitted to assess the factors associ-
ated with CNIP-induced haemodynamic instability.
Results: From the 118 patients included in the study, 764 CNIPs were analysed. Most of the patients were treated 
with norepinephrine for septic shock of medical origin (n = 83, 70 %). Haemodynamic instability occurred 114 times 
(15 %) in 63 patients (53 %). Among the risk factors identified by the univariate analysis (age, heart rate, dose of nor-
epinephrine infused, and change in the concentration of the vasoactive drug; p < 0.05), change in the norepinephrine 
concentration was the only independent risk factor for CNIP-induced haemodynamic instability identified in the 
multivariate analysis (adjusted OR 11.8, 95 % CI 7.2–19.5, p < 0.001).
Conclusions: Changes in the norepinephrine concentration during CNIPs lead to a high risk of haemodynamic insta-
bility, while the clinical severity of patients, as well as the doses of norepinephrine, was not.
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Background
Norepinephrine is widely used as a first-line treatment 
to support blood pressure in critically ill patients [1]. 
Because of its narrow therapeutic range and very short 
half-life, all undesired changes in norepinephrine flow 
rates may lead to acute and potentially life-threatening 
changes in mean arterial pressure (MAP) [2]. In numer-
ous countries, and almost all of Europe, norepinephrine 
is administered through high-precision electric syringe 
pumps [2–4]. As the volume of the syringes is limited 
(e.g. 60 ml for adults), changeovers of the norepinephrine 
infusion pumps (CNIPs) generally occur several times a 
day in an intensive care unit (ICU). Maintaining a con-
stant flow rate during CNIP is challenging, and haemo-
dynamic instability has been reported in up to one-third 
of vasoactive infusion pump relays [2–7].
Most of the research on CNIP has concentrated on 
determining the best method for performing these relays 
[2–8]. To date, it has been established that (1) the use of 
two syringe pumps (versus one), with or without an over-
lapping period, better ensures the continuity of the infu-
sion, (2) the standardisation of the relay procedure limits 
haemodynamic incidents, and (3) the automation of the 
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relay’s procedure, using smart pumps, further improves 
this routine care [2–8]. However, factors that are not 
linked to the methods, such as patient characteristics 
(including age, sex, type of shock, organ failures, and 
organ supports) and norepinephrine administration (e.g. 
concentration of the drug, flow rate, or dose), might also 
influence haemodynamic stability during CNIP.
Therefore, the aim of the study was to determine risk 
factors associated with CNIP-induced haemodynamic 
instability, regardless of the relay method, in order to 
identify new ways to further improve the safety of this 
procedure in the ICU.
Methods
We performed a prospective, observational study, over a 
1-year period in a university-affiliated 15-bed intensive 
care unit. This study was carried out during routine care 
with information of the patients or their relatives. Ethical 
approval was obtained from the ethics committee of the 
Hospices Civils de Lyon. This Institutional Review Board 
waived the need for consent given the nature of the study. 
The study was performed in compliance with the ethical 
standards detailed in the 1964 Declaration of Helsinki 
and according to French laws.
Patients
All consecutive adult patients treated for shock with a 
continuous norepinephrine perfusion through a central 
venous catheter, and who had at least one CNIP, were 
included in the study. Invasive arterial blood pressure was 
continuously monitored (Intellivue MP monitor, Philips 
Medical Systems, the Netherlands) and recorded on a 
PC-based data acquisition system supported by Intel-
liSpace Critical Care and Anaesthesia (ICCA) software 
(Philips Medical System, the Netherlands). No change in 
haemodynamic management for cardiovascular dysfunc-
tion occurred in our ICU during the study period.
The following data were collected for each patient: 
gender, age, type of admission (i.e. medical or surgical), 
type of shock, organ failures according to the Sequen-
tial Organ Failure Assessment (SOFA) score, Simplified 
Acute Physiology Score II (SAPS II), number of CNIPs 
during ICU stay, length of stay in the ICU, and outcome.
Norepinephrine administration
As previously described, norepinephrine was adminis-
tered using a 60-ml capacity luer-lock syringe (BD Plas-
tipack®, Octeville, France) and high-performance syringe 
pumps connected to a smart pump infusion workstation 
(Orchestra® Base Intensive, Fresenius Kabi/Vial, Brezins, 
France), through a three-lumen central venous line [5]. 
The proximal lumen was always dedicated to the vasoac-
tive drug infusion, and a low dead volume extension line 
with three-way stopcock (PES3101, Biocath®, Lissieu, 
France) was connected to this lumen in order to perform 
the CNIP. The initial dose of norepinephrine was deter-
mined empirically according to the severity of the shock 
state. Dose of norepinephrine was adjusted, as frequently 
as needed, to maintain haemodynamics.
Preparation of norepinephrine infusion
At initiation of the treatment, dilution of norepineph-
rine (in 0.9 % sodium chloride) was left to the discretion 
of the physician to obtain one of the following concen-
trations: 0.17, 0.33, 0.50, 0.67, 0.83 and 1  mg  ml−1. The 
purpose was to obtain an initial flow rate >2  ml  h−1 to 
limit the time elapsed between the start-up of the infu-
sion and the effective drug administration to the patient 
and <10  ml  h−1 to limit the frequency of CNIP. Nurses 
were allowed to change the norepinephrine dilution at 
the time of the CNIP (i.e. when the volume of infusion 
was almost depleted) in order to maintain the flow rate in 
the predefined range (i.e. 2–10 ml h−1). Our standardised 
protocol was continuously available in a specific form in 
the ICU, and all the nurses received periodic refresher 
courses.
Automated changeovers of norepinephrine infusion 
pumps
Changeovers of vasoactive drug’s syringes were per-
formed up to 2 h before the end of the ongoing infusion. 
As previously described, the automated relay procedure 
that was provided by the smart pumps consisted of two 
associated channels, which infused the drug, one after 
the other, at the same dose [5]. Accordingly, when the 
concentration of the vasoactive drug changed in the 
course of the CNIP, the smart pump automatically modi-
fied the flow rate of the new infusion pump to maintain 
a constant dose of norepinephrine. Syringe pumps were 
connected to data acquisition system with automatic 
storage of flow rates and doses.
CNIP-induced haemodynamic instability was defined 
as a variation of MAP  >  25  %, compared to the base-
line, occurring within 30  min after the changeover. The 
treatments of the incidents were left to the appreciation 
of the physicians in charge of the patients and were not 
recorded.
Statistical analysis
Categorical variables are expressed as counts and per-
centages and continuous variables as medians and inter-
quartile ranges (IQRs), as appropriate. Comparisons of 
categorical variables were performed using two-sided 
Fisher’s exact tests. Continuous data were compared 
using the Mann–Whitney U test or Friedman’s test, as 
appropriate.
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Factors associated with CNIP-induced haemodynamic 
instability were analysed by two-level mixed effects logis-
tic regression (MELR) modelling. This model is derived 
from the generalised linear mixed model, and it allowed 
the estimation of both fixed effects (i.e. factors related to 
the syringe changeover) and random effects (i.e. related 
to the patient) [5, 7, 9]. The outcome was CNIP-related 
haemodynamic instability, as defined above. The two lev-
els of the model were the characteristics of the changeo-
ver (Level 1) and of the patient (Level 2). The following 
explanatory data were related to the changeover: MAP, 
heart rate, organ supports, mechanical ventilation, renal 
replacement therapy, changeover order category (1st, 
2nd–5th, >5th), norepinephrine concentration (mg ml−1), 
flow rate (ml h−1), doses (μg kg−1 min−1), and the change 
in the infused norepinephrine concentration. The follow-
ing explanatory variables related to the patient were: gen-
der, age category (<45  years, 45–59  years, 60–74  years, 
≥75  years), SOFA score category (<10, 10–14, 15–19, 
≥20), SAPS II category (<50, 50–64, 65–80, ≥80), type of 
admission (medical, surgical), and type of shock (septic, 
cardiogenic, haemorrhagic, other).
Covariates with a p < 0.15 after univariate MELR analy-
sis were entered in the initial multivariate MELR model. 
MAP before CNIP was forced in the multivariate analy-
sis. A stepwise backward process was then performed 
until all p values were <0.05, and models were compared 
using the Wald test. Odds ratios (ORs) are expressed fol-
lowed by the 95 % confidence intervals (95 % CI).
 Stata 11 software (StataCorp. 2009. Stata Statistical 
Software: Release 11. College Station, TX: StataCorp LP) 
was used for analysis. Statistical significance was defined 
as a p value of <0.05. All tests were two-tailed.
Results
Over the study period, we included 118 ICU patients, in 
whom 764 CNIPs were performed. As shown in Table 1, 
most of the patients were male (sex ratio of 2.4) and were 
admitted to the ICU for septic shock of medical origin 
(n = 83, 70 %). A majority of the patients (n = 63, 53 %) 
experienced at least one episode of haemodynamic insta-
bility during CNIP (Table 1). In these patients, both the 
SOFA score and the number of CNIP were significantly 
higher (p < 0.01) than in patients without CNIP-related 
incidents (Table 1).
Characteristics of the 764 CNIP are reported in 
Table  2. A total of 114 (15  %) CNIP-related haemody-
namic incidents were observed. Haemodynamic insta-
bility was significantly more frequent when patients 
received mechanical ventilation, when norepinephrine 
doses and flow rates were lower, and when there was a 
change in the concentration of norepinephrine (p < 0.05). 
Type and magnitude of incidents are depicted in Table 3. 
As expected, haemodynamic instability was an increase 
in MAP in 40/43 (93 %) CNIPs with decrease in norepi-
nephrine concentration, whereas it was a drop in MAP in 
13/15 (87 %) CNIPs with increase in norepinephrine con-
centration. No sustained ventricular arrhythmia and no 
cardiac arrest were directly attributed to a CNIP-related 
haemodynamic incident.
After univariate MELR analysis, age, heart rate, dose of 
norepinephrine, and change in norepinephrine concen-
tration were significantly associated with haemodynamic 
incidents (Table  4). Gender, type of admission, type of 
shock, SAPS II score, SOFA score, MAP, mechanical ven-
tilation, renal replacement therapy, norepinephrine infu-
sion concentration and flow rates, and CNIP order were 
not linked with the risk of haemodynamic incident (data 
not shown). After multivariate MELR analysis, change in 
norepinephrine concentration was the only independ-
ent factor associated with an increased risk of haemo-
dynamic incident (adjusted OR 11.8, 95  % CI 7.2–19.5, 
p  <  0.001). Among CNIP with a change in norepineph-
rine concentration, hemodynamic instability was more 
likely to occur with low norepinephrine doses and when 
the drug concentration decreased (Table 5).
Table 1 Patient characteristics
SOFA Sequential Organ Failure Assessment, SAPS II Simplified Acute Physiology 
Score II
a Incident during changeover of norepinephrine syringe pumps (CNIP) was 
defined as a change in mean arterial pressure (MAP) >25 %
b Data are expressed as number (%) of patients








Male sexb 83 (70) 39 (71) 44 (70) >0.99
Age (years)c 63 (48–75) 63 (44–72) 63 (51–76) 0.35
Type of admissionb 0.75
 Medical 108 (92) 51 (93) 57 (90) –
 Surgical 10 (8) 4 (7) 6 (10) –
Type of shockb 0.23
 Septic 88 (75) 39 (71) 49 (78) –
 Cardiogenic 12 (10) 4 (7) 8 (13) –
 Haemorrhagic 10 (8) 6 (11) 4 (6) –
 Other 8 (7) 6 (11) 2 (3) –
Fluid loading 
(litres)c
3.7 (2.4–5.4) 3.5 (2.2–5.4) 3.8 (2.6–5.4) 0.35
SOFA scorec 12 (8–15) 11 (8–13) 13 (9–16) <0.01
SAPS IIc 59 (44–78) 53 (43–71) 61 (50–84) 0.06
ICU length of 
stay (days)c
8 (5–17) 6 (3–14) 11 (6–20) <0.01
Number of 
CNIPc
4 (2–9) 2 (1–4) 8 (4–13) <0.001
Survivalb 67 (57) 36 (65) 31 (49) 0.07
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Discussion
In the present work, the change of the norepinephrine 
concentration during CNIP was the sole independent risk 
factor for blood pressure instability following this routine 
care, regardless of the method used for the norepineph-
rine syringe CNIP, which was automated and standard-
ised. Contrary to popular belief, norepinephrine doses 
and flow rates, as well as the patient’s level of clinical 
severity, were not independently associated with CNIP-
related haemodynamic instability. However, among 
changeovers with a change in norepinephrine concentra-
tions, haemodynamic instability was more likely to occur 
with low dose of norepinephrine and when the drug con-
centration was decreased.
In this study, we observed haemodynamic instability in 
about 15 % of the CNIPs. This result agrees with the few 
studies published on this topic in which the frequency of 
haemodynamic incidents related to vasoactive infusion 
pump changeovers varied from 5 to 38  % [2–7, 10, 11]. 
Obviously, the frequency of these incidents depends on 
the definition of CNIP-induced haemodynamic instability, 
which is not consensual [2–7, 10, 11]. We chose to define 
haemodynamic instability as a relative change in MAP 
rather than an absolute change in MAP. Indeed, the risk 
with choosing an absolute value is the underestimation of 
CNIP-induced haemodynamic instability in patients with 
Table 2 Characteristics of the changeovers of norepineph-
rine syringe pumps
a Incident during changeover of norepinephrine syringe pumps (CNIP) was 
defined as a change in mean arterial pressure (MAP) >25 %
b Data are expressed as number (%) of patients









 MAP (mmHg)c 67 (59–76) 67 (59–76) 67 (59–74) 0.70




729 (95) 616 (95) 113 (99) 0.04
 Renal  
replacement 
therapy
470 (62) 397 (61) 73 (64) 0.60
Norepinephrine infusionc
 Flow rates 
(ml h−1)
5.4 (3.3–7.8) 5.7 (3.5–8.0) 4.0 (2.8–6.6) 0.001
 Doses (μg kg−1 
min−1)
0.6 (0.2–1.1) 0.6 (0.2–1.2) 0.4 (0.2–1.0) <0.01
Norepinephrine concentration
 Concentration  
(mg ml−1)c
0.5 (0.2–0.5) 0.5 (0.25–0.5) 0.5 (0.5–0.5) 0.68
 No change in 
concentrationb
650 (85.1) 594 (91.4) 56 (49.1) <0.0001
 Change in  
concentrationb
114 (14.9) 56 (8.6) 58 (50.9) <0.0001
  Decrease 68 (8.9) 25 (3.8) 43 (37.7) <0.0001
  Increase 46 (6.0) 31 (4.8) 15 (13.2) <0.001
CNIP orderb 0.95
 First 118 (15) 101 (16) 17 (15) –
 2–5th 297 (39) 251 (39) 46 (40) –
 >5th 349 (46) 298 (46) 51 (45) –
Table 3 Type and magnitude of haemodynamic incidents
a Incident during changeover of norepinephrine syringe pumps (CNIP) was defined as a change in mean arterial pressure (MAP) >25 %
b Data are expressed as number (%) of patients
c Data are expressed as median values and IQRs
All CNIP with incidentsa
(n = 114)
CNIP with no change  
in concentration
(n = 56)






Increase in MAP > 25 %b 83 (73) 41 (73) 2 (13) 40 (93)
 Variation in MAP (%)c 33 (25–49) 31 (28–38) 27 (32–37) 36 (29–54)
 Variation in MAP (mmHg)c 22 (17–32) 19 (15–25) 32 (27–37) 27 (20–35)
Decrease in MAP > 25 %b 31 (27) 15 (27) 13 (87) 3 (7)
 Variation in MAP (%)c 33 (29–39) 33 (29–39) 33 (29–41) 26 (25–30)
 Variation in MAP (mmHg)c 21 (19–28) 26 (20–30) 21 (19–31) 22 (17–23)
Table 4 Factors associated with haemodynamic incidents, 
univariate mixed effects logistic regression
OR odds ratio, CI confidence intervals
Crude OR (95 %CI) p
Age category (years)
 <45 1.00 (Ref.) –
 45–59 2.3 (1.1–4.5) 0.02
 60–74 1.5 (0.8–2.9) 0.25
 ≥75 2.0 (1.0–4.1) 0.05
Heart rate: per 10 bpm 0.9 (0.8–1.0) 0.04
Norepinephrine dose: per 1 μg kg−1 min−1 0.7 (0.5–0.9) 0.01
Change in concentration 11.8 (7.2–19.5) <0.001
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the lowest MAP. We defined haemodynamic instability as 
a CNIP-induced variation of MAP > 25 %. This threshold 
seemed clinically significant and corresponds to an abso-
lute change of MAP of 15–20  mmHg for septic shock 
patients to obtain a therapeutic blood pressure target of 
around 70  mmHg. Because previous studies comparing 
methods of CNIP used similar norepinephrine concentra-
tions in the two syringes, frequency of CNIP-related inci-
dents may have been underestimated by comparison with 
“real life” [2–8, 10, 11]. Indeed, it is often necessary in 
clinical practice to change the concentration of the norep-
inephrine infusion throughout the administration of the 
drug. To the best of our knowledge, little data are available 
on changeover with changes in norepinephrine concen-
tration. In the present work, while CNIP with changes in 
norepinephrine concentration represented almost 1/6 of 
the changeovers, they accounted for half of the haemody-
namic incidents.
We found that the only independent factor associated 
with CNIP-induced blood pressure instability was the 
change in the norepinephrine concentration. Contrary 
to what one might expect, the frequency of CNIP-related 
incidents was not independently associated with the nor-
epinephrine doses infused into the patients and had no 
link to the severity of the shock. An important implica-
tion of this observation is that special care must be taken 
in all patients when performing CNIP, even in those with 
low doses of norepinephrine. Importantly, we took into 
account, in the most appropriate way, all of the usual fac-
tors known to alter the continuity of the norepinephrine 
infusion during CNIP (e.g. low flow rates, entrapped air 
in the perfusion line, vertical displacements of syringe 
pumps) [2, 12–14]. Above all, we used the safest available 
method to perform CNIP [5, 7, 8]. Indeed, both recent 
basic evidence and clinical evidence have suggested that 
the automation of a CNIP method without overlapping 
the perfusions (i.e. “quick change”), using smart pumps, 
better maintains the delivered norepinephrine doses 
and further improves blood pressure stability during the 
syringe changeovers [5, 7, 8].
Considering the number of haemodynamic incidents 
occurring when there is a change of norepinephrine con-
centration during CNIP, our study raises the problem of 
the use of several concentrations of norepinephrine in 
the ICU. We believe that the use of several dilutions of 
norepinephrine is of great clinical interest. Indeed, doses 
of norepinephrine may vary widely during the treatment 
of shock [15]. Thus, the use of a single dosage form of 
norepinephrine brings with it the possibility of adminis-
tering the vasoactive drug at very low or very high flow 
rates. It is well known that small flow rates delay the 
delivery of a drug to the patient during treatment initia-
tion, especially when the dead space of the infusion sys-
tem is important [16–19]. It is reasonable to assume that 
such low flow rates play a role in altering the continuity 
of perfusion during CNIP. However, as flow rates were 
maintained at >2 ml h−1 in almost all patients at the time 
of the CNIP, our study does not answer whether low flow 
rates also alter the continuity of perfusion during CNIP. 
By contrast, high flow rates (e.g. >10  ml  h−1) accelerate 
the emptying of the syringe and consequently increase 
the frequency of CNIP, which represents a high-risk 
period of haemodynamic instability [2–6, 10, 11].
Our results suggested that an automated “quick 
change” was probably not optimal for CNIP with changes 
in norepinephrine concentrations, particularly at low 
doses. Obviously, in the event of a change in the nor-
epinephrine concentration during CNIP, the vasoactive 
drug solution occupying the dead space of the perfu-
sion line is administered for some time at an undesired 
dose (depending on the drug concentration in the ending 
syringe and the flow rate of the new syringe pump). Con-
sequently, this may induce a transient over- or under-
dose. For this reason, the number of CNIP with changes 
in norepinephrine concentrations should be limited as far 
as possible. We can hypothesise that the “double pump-
ing” method, which provides an overlapping of the perfu-
sions, might limit this inconvenience [3]. However, it is 
acknowledged that this process is time-consuming and 
not automatically provided by the current generation of 
Table 5 Interaction between  the norepinephrine dose and  the risk of  CNIP-induced haemodynamic instability based 
on changes in the norepinephrine concentration
CNIP Changeover of norepinephrine syringe pumps, OR odds ratio, CI confidence intervals
a After multivariate mixed effects logistic regression
Overall (n = 764) Dose < 0.5 μg kg−1 min−1 (n = 324) Dose ≥ 0.5 μg kg−1 min−1 
(n = 440)
Adjusted ORa (95 % CI) p Adjusted ORa (95 % CI) p Adjusted ORa (95 % CI) p
No change in concentration 1.00 (Ref.) – 1.00 (Ref.) – 1.00 (Ref.) –
Decrease in concentration 20.7 (11.0–39.0) <0.001 28.9 (13.5–61.8) <0.001 7.8 (1.5–41.3) <0.01
Increase in concentration 5.4 (2.7–10.9) <0.001 33.2 (6.0–182.3) <0.001 3.4 (1.4–8.1) <0.01
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smart pumps [3, 5]. Automated “quick change” might 
be easily improved by integrating the dead space of the 
perfusion line into the smart pumps’ algorithms. Future 
research is therefore required to address the important 
issue of safety during CNIP in the subgroup of changeo-
vers with a change in norepinephrine concentration.
Whether CNIP-induced haemodynamic instability 
has an impact on clinical outcomes remains uncertain. 
Although our study was the largest on CNIP, it was not 
sufficiently powered to assess this important issue. It 
remains also unclear whether CNIP-induced increase in 
MAP, which occurred in the three quarters of the cases 
in our study, is less deleterious than CNIP-induced hypo-
tension. This probably depends on both patients and 
types of shock (e.g. septic versus haemorrhagic) and on 
the magnitude of change in MAP. A final important ques-
tion is still pending: how to manage the stressful CNIP-
induced hemodynamic incidents? Further research is 
needed to answer these questions.
Conclusions
Our results emphasise that the risk of haemodynamic 
incident during the CNIP is not linked to the sever-
ity of the shock or to the characteristics of the patients. 
Haemodynamic instability remains a high risk when the 
norepinephrine concentration is changed during CNIP. 
Further studies are needed to determine the best method 
for CNIP when a change in the norepinephrine concen-
tration is required.
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